menu

THE 5AM PORTFOLIO: COMPANY PROFILES

Achaogen

Achaogen (AKAO) is a biopharmaceutical company developing small molecule therapeutics to treat infections caused by multi-drug resistant bacterial. IPO in March 2014.

Alexza

Alexza (ALXA) is a biopharmaceutical company developing drugs for local and systemic delivery through the lung. IPO in March 2006.

Ambrx

Ambrx is a biopharmaceutical company which integrates recombinant protein synthesis with medicinal chemistry to develop protein drugs for a range of therapeutic areas. Acquired in June 2015.

Aprea

Aprea is a biopharmaceutical company developing small molecule therapeutics for the treatment of cancer by reactivating mutant p53 tumor suppressor function.

Arvinas

Arvinas is a biopharmaceutical company developing small molecule therapeutics that target protein degradation with applications in cancer and other diseases.

Audentes

Audentes (BOLD) is a biotechnology company developing viral-based gene therapy for serious, rare diseases including genetic musculoskeletal disorders. IPO in July 2016.

Bellerophon

Bellerophon (BLPH) is a clinical-stage biopharmaceutical company developing novel drugs and devices for the treatment of cardiopulmonary and cardiac diseases. IPO in February 2015.

BIODESY

Biodesy is a life science instrument and reagent company developing innovative technology systems for measuring protein conformational changes in real time.

Bird Rock Bio

Bird Rock Bio is a clinical-stage biopharmaceutical company developing biologic therapies for the treatment of rheumatory arthritis and liver disease.

Calibrium

Calibrium is a biopharmaceutical company developing next generation insulins to treat diabetes and obesity. Acquired by Novo Nordisk (NVO) in August 2015.

Cellular Research

Cellular Research is a life science instrument company developing high resolution systems for the investigation of single cells and limited samples. Acquired by Becton Dickinson (BDX) in August 2015.

Ceterix Orthopedics

Ceterix is a medical device company developing products to improve outcome for minimally invasive arthroscopic surgeries.

Chrono

Chrono is a biopharmaceutical company developing wearable and programmable therapeutics leveraging novel drug delivery technologies.

Cidara

Cidara (CDTX) is a clinical-stage biopharmaceutical company developing therapeutics for serious fungal infections. IPO in April 2015.

Cleave Biosciences

Cleave is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics that target protein homeostasis pathways for the treatment of cancer.

Crinetics

Crinetics is a biopharmaceutical company developing oral small molecule therapeutics for endocrine diseases.

DVS Sciences

DVS is a life science instrument company commercializing a mass cytometry for characterizing individual cells based on cell surface proteins. Acquired by Fluidigm (FLDM) in February 2014.

Envoy

Envoy is a drug discovery company with a cell-specific gene expression profiling platform, enabling novel target discovery, such as for the central nervous system. Acquired by Takeda (TKPHF) in November 2012.

Epirus

Epirus (EPRS) is a global biopharmaceutical company focused on pure-play biosimilar business to improve patient access to cost-effective medicines. Merged into public company in July 2014.

Flexion

Flexion (FLXN) is a clinical-stage biopharmaceutical company developing intra-articular sustained release therapeutics for the treatment of musculoskeletal diseases. IPO in February 2014.

GenePeeks

Novel genome analytics platform to quantify risk of rare disease inheritance.

Homology

Translating proprietary, next generation gene editing and gene therapy technology into novel treatments for patients with rare diseases.

IDEAYA

Small molecules as novel personalized cancer therapies, leveraging synthetic lethality and immuno-oncology.

Igenica

Igenica is a biopharmaceutical company developing antibodies and antibody-drug conjugates for the treatment of cancer.

Ikaria

Ikaria is a commercial-stage biopharmaceutical company developing therapeutic gases for critical care applications. Acquired by Madison Dearborn Partners in February 2014.

Ilypsa

Ilypsa is a biopharmaceutical company developing non-absorbed therapeutics for renal and metabolic diseases. Acquired by Amgen (AMGN) in July 2007.

Impel Neuropharma

Impel Neuropharma is a drug delivery company developing intranasal treatments for central nervous system disorders

Incline

Incline is a biopharmaceutical company developing a transdermal iontophoretic patch for patient controlled analgesia following surgery. Acquired by The Medicines Company (MDCO) in January 2013.

Kalobios

KaloBios (KBIO) is a biopharmaceutical company developing human antibody therapeutics for oncology and respiratory diseases. IPO in January 2013.

Kinestral

Kinestral is a materials research company developing "adaptive" window technology for residential, automotive and commercial application.

Marcadia

Marcadia is a biopharmaceutical company focused on developing therapeutics for the treatment of diabetes and obesity. Acquired by Roche (RHHBY) in December 2010.

Miikana

Miikana is a clinical-stage biopharmaceutical company developing small molecule therapeutics for cancer. Acquired by EntreMed, a 5AM company, in January 2006.

Millendo

Millendo is a biopharmaceutical company developing small molecule therapeutics for polycystic ovarian syndrome, adrenocortical carcinoma and congenital adrenal hyperplasia.

Nohla Therapeutics

Nohla Therapeutics is a clinical stage company developing ex vivo expanded universal donor cellular therapies, available on demand for treatment of life threatening diseases

Novira

Novira is a biopharmaceutical company developing small molecule therapeutics targeting viral capsid to treat Chronic Hepatitis B. Acquired by Johnson & Johnson (JNJ) in December 2015.

Panomics

Panomics is a research instrument and reagents company which develops cell-based assays and instruments for quantitative multiplexed measurements of molecular events. Acquired by Affymetrix (AFFX) in December 2008.

Pear

Pear is a biopharmaceutical company combining existing medications with digital software to improve patient outcomes.

Pearl

Pearl is a biopharmaceutical company developing inhalable formulations for the treatment of respiratory diseases such as chronic obstructive pulmonary disease. Acquired by AstraZeneca (AZN) in June 2013.

PhaseRx

PhaseRx (PZRX) is a biotechnology company developing polymer-based technology to delivery mRNA nanoparticles for the treatment of orphan diseases. IPO in May 2016.

Portal Instruments

Portal is a biopharmaceutical company developing needle-free drug delivery system for the injection of large molecules.

Precision NanoSystems

PNI is a life science instrument and reagent company developing systems for the discovery and development of novel nanoparticles for biomedical use.

Pulmatrix

Pulmatrix (PULM) is a pharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases. Merged into public company in June 2015.

Purigen

Purigen is a life sciences instruments and reagents company developing novel systems for integrated sample extraction and preparation for genomics applications.

Relypsa

Relypsa (RLYP) is a commercial-stage biopharmaceutical company developing non-absorbed polymeric drugs, including a potassium-binding agent for hyperkalemia associated with cardiovascular and renal diseases. IPO in November 2013.

Rennovia

Rennovia is a materials research company developing chemocatalytic processes for converting biorenewable feedstocks into high value and commodity chemicals.

Scientist.com

Scientist.com is a marketplace solution for accelerating the pace of pharmaceutical research and development.

scPharmaceuticals

scPharmaceuticals is a biopharmaceutical company developing therapeutics with enhanced drug delivery using a convenient, self-administering subcutaneous micropump technology.

Semprus Biosciences

Semprus is a medical device company developing permanent antimicrobial and anti-biofouling surfaces for use on indwelling devices. Acquired by Teleflex (TFX) in May 2012.

Spyryx

Spyryx is a biopharmaceutical company developing inhaled small peptide therapeutics for lung diseases, in particular cystic fibrosis and COPD.

Synosia

Synosia is a biopharmaceutical company developing and commercializing products for neurodegenerative and psychiatric disorders. Acquired by Biotie, a 5AM company, in February 2011.

VBI Vaccines

VBI Vaccines is a biopharmaceutical company developing vaccines against Cytomegalovirus and other pathogens. Merged into public company in July 2014.

Viveve

Viveve (VIVE) is a medical device company commercializing a non-surgical, non-ablative medical device for use in women's health. Merged into public company in September 2014.

Wildcat

Wildcat is a materials research company  developing advanced battery materials for consumer and industrial applications.